We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Influenza Diagnostic Tests Evaluated

By LabMedica International staff writers
Posted on 26 Dec 2012
Accurate diagnosis of influenza is critical for clinical management, infection control, and public health actions to minimize the burden of the disease.

Rapid influenza diagnostic tests (RIDTs) that detect the influenza virus nucleoprotein (NP) antigen are widely used in clinical practice for diagnosing influenza because they are simple to use and provide results within 15 minutes.

A collaboration between the US Centers of Disease Control (CDC; Atlanta, GA, USA), and the Medical College of Wisconsin (MCW; Milwaukee, WI, USA) evaluated RIDTs commercially available during the 2011–2012 influenza season. The CDC provided 16 influenza A and seven influenza B viruses to MCW. The concentration of influenza virus NP antigen was measured as μg/mL using isotope dilution tandem mass spectrometry. Swab samples or mock nasal wash specimens were prepared from several dilutions of each virus in saline.

The numbers of RIDTs that were positive, defined as at least two positive results of the three tests performed, at each dilution for each of the 23 influenza viruses were compared. The RIDTs overall had fewer positive results with viruses that had the lowest stock NP concentrations of less than 2 µg/mL. One RIDT, the SAS FluAlert Influenza A (SA Scientific; San Antonio, TX, USA) did not uniformly detect influenza A (H1N1)pdm09 (pH1N1) viruses or other influenza A viruses at high concentrations. Four RIDTs detected the majority of influenza B viruses in the third dilution samples, whereas only one RIDT, the BD Directigen EZ Flu A+B (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) detected at least 50% of all influenza A viruses in the third dilution samples.

Clinicians should be aware of the variability of RIDTs when interpreting negative results and should collect test samples using methods that can maximize the concentration of virus antigen in the sample, such as collecting adequate specimens using appropriate methods in the first 24 to 72 hours after illness onset. The study was published on November 2, 2012, in the Morbidity & Mortality Weekly Report.

Related Links:

US Centers of Disease Control
Medical College of Wisconsin
Becton, Dickinson and Company



New
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Herpes Virus Test
Human Herpes Virus (HHV-6) Real Time PCR Kit
New
Tabletop Centrifuge
Mikro 185

Latest Microbiology News

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Innovative Diagnostic Approach for Bacterial Infections to Enable Faster and Effective Treatment